Cargando…
Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
[Image: see text] Proteolysis targeting chimera (PROTAC)-mediated protein degradation has prompted a radical rethink and is at a crucial stage in driving a drug discovery transition. To fully harness the potential of this technology, a growing paradigm toward enriching PROTACs with other therapeutic...
Autores principales: | Salerno, Alessandra, Seghetti, Francesca, Caciolla, Jessica, Uliassi, Elisa, Testi, Eleonora, Guardigni, Melissa, Roberti, Marinella, Milelli, Andrea, Bolognesi, Maria Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340767/ https://www.ncbi.nlm.nih.gov/pubmed/35816671 http://dx.doi.org/10.1021/acs.jmedchem.2c00302 |
Ejemplares similares
-
Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020) -
Shining a Light on Proteolysis Targeting Chimeras
por: Teichmann, Ellen, et al.
Publicado: (2019) -
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022) -
Proteolysis-targeting chimeras and their implications in breast cancer
por: Tecalco-Cruz, Angeles C., et al.
Publicado: (2021) -
The clinical advances of proteolysis targeting chimeras in oncology
por: Xie, Hao, et al.
Publicado: (2021)